Omalizumab with or without allergen immunotherapy reduces inhaled corticosteroid use in house dust mite-sensitized allergic asthma
Omalizumab, a monoclonal antibody targeting IgE, when combined with allergen immunotherapy for house dust mite sensitization, may reduce reliance on daily inhaled corticosteroids in patients with mild-to-moderate allergic asthma, according ... Read More